Page last updated: 2024-08-24

irinotecan and interleukin-8

irinotecan has been researched along with interleukin-8 in 10 studies

Research

Studies (10)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (30.00)	29.6817
2010's	5 (50.00)	24.3611
2020's	2 (20.00)	2.80

Authors

Authors	Studies
Kishida, O; Kiyohara, T; Miyazaki, T; Miyazaki, Y; Murayama, Y; Ogasa, M; Shimomura, I; Shinomura, Y; Tsutsui, S; Watabe, K; Yamamoto, T	2
Danenberg, KD; Fazzone, W; Gordon, M; Iqbal, S; Lenz, HJ; Rhodes, KE; Schultheis, AM; Sherrod, AE; Vallböhmer, D; Yang, DY; Zhang, W	1
Askenasy, N; Fabian, I; Halperin, D; Reuveni, D; Shalit, I; Tsarfaty, G	1
Bujok, K; Fromm, MF; Glaeser, H; Mandery, K; Rau, TT; Schmidt, I; Schuh, W	1
Gu, Y; Li, L; Li, Q; Wang, W; Wu, X; Xu, Q; Zhang, X	1
Jin, DY; Lou, WH; Rong, YF; Wu, W; Xu, XF; Zhang, L	1
Chai, ZT; Chen, J; Fang, Y; Liu, F; Ma, DN; Yin, XL; Zhang, N; Zhou, JM	1
Bazan, D; Cavaliere, A; Deiana, M; Fedele, V; Lonardi, S; Mangiameli, D; Melisi, D; Merz, V; Piro, G; Sabbadini, F; Santoro, R; Simionato, F; Valenti, MT; Zecchetto, C	1
Bowen, JM; Coller, JK; Prestidge, CA; Tam, JSY	1

Trials

1 trial(s) available for irinotecan and interleukin-8

Article	Year
Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 09-01, Volume: 26, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Interleukin-8; Irinotecan; Male; MAP Kinase Kinase Kinases; Mice; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Transcriptional Activation; Xenograft Model Antitumor Assays	2020

Article

Year

Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 09-01, Volume: 26, Issue:17

Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Interleukin-8; Irinotecan; Male; MAP Kinase Kinase Kinases; Mice; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Transcriptional Activation; Xenograft Model Antitumor Assays

2020

Other Studies

9 other study(ies) available for irinotecan and interleukin-8

Article	Year
Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells. Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:6 Topics: Amphiregulin; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Screening Assays, Antitumor; EGF Family of Proteins; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glycoproteins; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Irinotecan; Phosphorylation; Quinazolines; Reactive Oxygen Species; Signal Transduction; Stomach Neoplasms; Transforming Growth Factor alpha; Tyrosine	2005
Gefitinib ("Iressa", ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells. Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:4 Topics: Adenocarcinoma; Amphiregulin; Antineoplastic Agents; Camptothecin; EGF Family of Proteins; ErbB Receptors; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Irinotecan; Metalloproteases; Phosphorylation; Quinazolines; Reactive Oxygen Species; Stomach Neoplasms; Transforming Growth Factor alpha; Tumor Cells, Cultured	2005
Molecular determinants of irinotecan efficacy. International journal of cancer, 2006, Nov-15, Volume: 119, Issue:10 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Repair; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Irinotecan; Male; Middle Aged; Peptide Termination Factors; Polymerase Chain Reaction; Predictive Value of Tests; Retrospective Studies; RNA, Messenger; Treatment Outcome; Vascular Endothelial Growth Factor A	2006
Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors. Biochemical pharmacology, 2010, Apr-15, Volume: 79, Issue:8 Topics: Angiogenesis Inhibitors; Animals; Anti-Infective Agents; Antineoplastic Agents; Aza Compounds; Camptothecin; Cell Proliferation; Drug Synergism; Female; Fluoroquinolones; Humans; Interleukin-8; Irinotecan; Mice; Mice, SCID; Moxifloxacin; Neoplasms, Experimental; Platelet Endothelial Cell Adhesion Molecule-1; Quinolines; Ultrasonography, Doppler; Xenograft Model Antitumor Assays	2010
Interplay between the prostaglandin transporter OATP2A1 and prostaglandin E2-mediated cellular effects. Cellular signalling, 2015, Volume: 27, Issue:3 Topics: Camptothecin; Cell Movement; Cell Survival; Cyclic AMP; Dinoprostone; Gastric Mucosa; HEK293 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Interleukin-8; Irinotecan; Organic Anion Transporters; Receptors, Prostaglandin E, EP4 Subtype; RNA, Messenger; S Phase Cell Cycle Checkpoints; Up-Regulation	2015
CPT-11 activates NLRP3 inflammasome through JNK and NF-κB signalings. Toxicology and applied pharmacology, 2015, Dec-01, Volume: 289, Issue:2 Topics: Animals; Anti-Inflammatory Agents; Camptothecin; Carrier Proteins; Caspase 1; Cell Line, Tumor; Colitis; Colon; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Inflammation Mediators; Interleukin-1beta; Interleukin-8; Irinotecan; JNK Mitogen-Activated Protein Kinases; Lipopolysaccharides; Macrophages; Mice, Inbred C57BL; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Permeability; Protein Kinase Inhibitors; Signal Transduction; Time Factors; Topoisomerase I Inhibitors	2015
SN38 increases IL-8 expression through the MAPK pathways in HCT8 cells. International journal of molecular medicine, 2017, Volume: 39, Issue:1 Topics: Berberine; Camptothecin; Cell Line, Tumor; Cell Survival; Fluorouracil; Humans; Interleukin-8; Irinotecan; Janus Kinase 2; MAP Kinase Signaling System; Phosphorylation; Quinazolines; Up-Regulation	2017
Berberine hydrochloride counteracts enhanced IL-8 expression induced by SN 38 in AGS cells. Journal of Asian natural products research, 2018, Volume: 20, Issue:8 Topics: Apoptosis Regulatory Proteins; Berberine; Cell Adhesion; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Cell Proliferation; Human Umbilical Vein Endothelial Cells; Humans; Interleukin-8; Irinotecan; MAP Kinase Signaling System; p38 Mitogen-Activated Protein Kinases; Topoisomerase I Inhibitors	2018
Investigation of TLR4 Antagonists for Prevention of Intestinal Inflammation. Inflammation, 2023, Volume: 46, Issue:1 Topics: Animals; Humans; Inflammation; Interleukin-6; Interleukin-8; Irinotecan; Lipopolysaccharides; Mice; Mucositis; Toll-Like Receptor 4; U937 Cells	2023